Apollo Endosurgery — Investor Presentation (October 2021)
39 slides from Apollo Endosurgery's investor presentation, Oct 12, 2021
Slide 1: Transforming therapeutic endoscopy
O C T O B E R 2 0 2 1 Transforming therapeutic endoscopy
Slide 2: Forward Looking Statements & Regulatory Advisory
Forward Looking Statements & Regulatory Advisory Forward Looking Statements: Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amended
Slide 3: Disclaimers
Disclaimers 3 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such an offer or solicitation in such jurisdiction. This presentation contains information regarding the Company’
Slide 4: New strategy
new strategy Transforming growth trajectory by prioritizing key initiatives: energize lead Expand penetration by advancing commercial traction & awareness accelerate Build clinical support for new indications that open door to new, large markets Execute to become the standard of care new team New CE
Slide 5: Our Story: Executing on milestones to catalyze rapid long-term growth
New CEO FDA Breakthrough Device Designation Orbera for NASH New CFO New VP of Sales & VP of Marketing Our Story Executing on milestones to catalyze rapid long-term growth 2022E De Novo 510(k) Classification Request for Apollo ESG & Apollo REVISE for weight loss & bariatric revisions Anticipated laun
Slide 6: Motivated, Experienced Leadership Team
Motivated, Experienced Leadership Team Kirk Ellis David Hooper Chas McKhann Jeff Black P R E S I D E N T & C E O C F O C M O Christopher Gostout, M.D. E X E C U T I V E V P , O P S John Molesphini 25 years of experience in med- device CEO & CCO roles with track record of developing effective growth
Slide 7: Energizing to Transform Growth
Energizing to Transform Growth Continued traction in 2021* speaks to strong momentum YoY revenue growth YTD 60% 62% ESS revenue growth YTD 72% X-Tack revenue from re-orders ✓ Primary & secondary endpoints met in MERIT; De Novo 510K Classification Request 33% growth YTD compared to 2019 YTD1 Apollo E
Slide 8: Less-Invasive Portfolio Treats Unmet Needs
Less-Invasive Portfolio Treats Unmet Needs • ESD or EMR site closure • POEM • Stent fixation • Intragastric balloon • Endoscopic revisions of prior bariatric surgery (e.g., gastric bypass) • Endoscopic sleeve gastroplasty (ESG) (De Novo 510K filed in Q3 2021) • Fistula, perforation, other GI tissue
Slide 9: Line of sight to near- and long-term value creation
Line of sight to near- and long-term value creation endoscop ic su tu r i ng sys tem endoscop ic he l i x t ack ing sys tem Increase number of users & range of applications; build foundation for endoscopic weight loss Build utilization of X-Tack as a valuable new tool for defect closer in upper & lo
Slide 10: Expanding the addressable market
Expanding the addressable market ADDRESSABLE GLOBAL MARKET HISTORICALLY Advanced GI defect closure Intragastric Balloons ~$215M FUTURE ADDRESSABLE GLOBAL OPPORTUNITY (Exclusive of market growth)~$7.7B $175M $40M New products New applications Clinical support Reimbursement 1. Verified Market Research
Slide 11: Advanced Gastro-Intestinal Therapies
Advanced Gastro- Intestinal Therapies
Slide 12: Establishing Leadership in GI Defect Closure
Establishing Leadership in GI Defect Closure 12 Expanding penetration of upper GI defect closures… A D V A N C E D G A S T R O I N T E S T I N A L T H E R A P I E S Establishing suturing as the standard of care: • Stent Fixation • ESD or EMR site closure • POEM • Fistula, perforation & other GI trac
Slide 13: OverStitch Endoscopic Suturing System (ESS)
65%15% 20% OverStitch Endoscopic Suturing System (ESS) Enhancing medical education for new & advancing users Developing procedure & clinical data Progressing toward ESG indication, which dominates international mix (OUS) GROWTH DRIVERS ESG dominates mix O.U.S. A D V A N C E D G A S T R O I N T E S T
Slide 14: X-Tack Endoscopic Helix Tacking System
14 X-Tack Endoscopic Helix Tacking System THE NEXT EVOLUTION IN DEFECT CLOSURE • Enabling technology addresses defects created during resection or dissections in upper & lower GI GROWTH DRIVERS A D V A N C E D G A S T R O I N T E S T I N A L T H E R A P I E S • Colonoscope & gastroscope compatible •
Slide 15: Expanding to Common GI Procedures
21M 2.3 U.S. colonoscopies per year1 6% THE NEW STANDARD OF CARE FOR A VAST UNMET NEED 15 Expanding to Common GI Procedures 1. Decision Resource Group: Gastrointestinal Endoscopy Devices, Medtech 360, Market Analysis, US 2016 | 2. Am Journal of Gastroenterol 2020;115:774–782. | 3. Pohl H., et al. Cl
Slide 16: Endobariatric
sSapollo “2 endosurgery_ Endobariatric
Slide 17: Building Access to Large Untapped Markets
Building Access to Large Untapped Markets E N D O B A R I A T R I C $1.0B Estimated Global Addressable Market6 R E V I S I O N S +>$2.9B O B E S I T Y <0.2% 1. NHANES 2017-2018; US Census 2020; ASMBS; management estimates | 2. O’Brien P. Surgical Treatment of Obesity. Endotext (Internet). | 3. World
Slide 18: Framing our opportunity
framing our opportunity S E E K S U R G I C A L T R E A T M E N T 1818
Slide 19: Extending Application of OverStitch to Endoscopic Revisions of Bariatric Surgeries
Anatomically-driven weight regain following weight loss surgery can be addressed with endoscopic surgical revision. Extending Application of OverStitch to Endoscopic Revisions of Bariatric Surgeries 19 E N D O B A R I A T R I C 1.4MU.S. laparoscopic sleeve & gastric bypasses 2011 to ’191 43K U.S. re
Slide 20: OverStitch for ESG Could Shift the Weight Loss Paradigm
Endoscopic Sleeve Gastroplasty is intended to be a minimally invasive, endoscopic weight loss procedure, utilizing OverStitch™ to reduce stomach volume OverStitch for ESG Could Shift the Weight Loss Paradigm 20 1. Internal meta-analysis of published ESG studies. | 2. Neto, M., et al. Brazilian Conse
Slide 21: New Development in Obesity Treatment
New Development in Obesity Treatment 1. 58 participants undergoing ESG in a small, randomized study were assigned to take semaglutide at a maximum dose of 1.5 mg/week or placebo, starting from within 1 month of the procedure. From around 6 months, weight loss in the semaglutide group began to outstr
Slide 22: Driving Clinical, Regulatory, & Reimbursement ESG Support Via MERIT Study
Driving Clinical, Regulatory, & Reimbursement ESG Support Via MERIT Study 22 1. Dr. Barham Abu Dayyeh. Mayo Clinic Professor of Medicine & Director of Advanced Endoscopy. . | See Product Regulatory Advisory, slide 2 D E S I G N PA R T I C I PA N T S E N D P O I N T S S TAT U S Multi-center randomize
Slide 23: Leading Gastric Balloon Worldwide
Leading Gastric Balloon Worldwide 23 1 2 3 4 Shah, R, et al. Spotlight: Intragastric Balloons in the Management of Obesity. Clinical Practice Guideline. Volume 160, Issue 5. April 2021. | 1. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. Journal of Gastrointestinal Endoscopy. 201
Slide 24: Improving Access to Care
broader coverage • Replicate existing successful models • Build on prior authorization successes with support capability • New CPT codes + coding for outpatient facilities • Payer engagement & education • Leverage experience and data to establish coverage policies energize accelerate lead Improving
Slide 25: NASH Opportunity
sSapollo = Sndosureee NASH Opportunity
Slide 26: NASH Opportunity
N A S H O P P O R T U N I T Y 2 0 1 9 2 0 2 7 E ~59% C A G R KYMBERLY WATT Gastroenterologist Mayo Clinic Rochester All of the risk factors for NASH are not going away. They're getting worse.4“ “ 1. Reports and Data. Non-Alcoholic Steatohepatitis (NASH) Market Analysis By Disease Cause (Hypertension
Slide 27: Our EWL Solutions May Help
Non-alcoholic steatohepatitis, a severe form of fatty liver disease can progress to cirrhosis and liver failure Our EWL Solutions May Help 27 1. Bazerbacki, F. et al. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis
Slide 28: Commercial Priorities
sSapollo = Sndosureee Commercial Priorities
Slide 29: Leveraging Strong Academic Presence
Leveraging Strong Academic Presence 20 of top 20 U . S . r e s e a r c h h o s p i t a l s 1 25 of top 25 G . I . s p e c i a l i z e d h o s p i t a l s 1 Well-positioned to both expand academic stronghold and broaden usage 1. U.S. News and World Report29
Slide 30: Revitalizing the Sales Network
Revitalizing the Sales Network New leadership + increasing opportunities attracting high-caliber professionals globally • Experienced reps returning to Apollo • Increasingly attracting from peers ~30 D I R E C T U . S . R E P S E N E R G I Z E ~50 ~70 A C C E L E R A T E L E A D • New growth opportu
Slide 31: Significant Catalysts Ahead
Significant Catalysts Ahead endoscopic sutur ing system endoscopic hel ix tack ing system managed weight loss system 2022 De Novo 510(k) Classification Request for Apollo ESG & Apollo REVISE for weight loss & bariatric revisions 2021 2022E 2023E 024E Anticipated launch of Apollo ESG and Apollo REVIS
Slide 32: Financials
sSapollo eee ca Fifene chai
Slide 33: Revenue
Revenue 33 Q3 2020 Q3 2021 YoY YTD Q1-Q3 2020 YTD Q1-Q3 2021 YoY ESS $ 7.6M $10.1M +32% $18.1M $29.4M +62% IGB $ 4.9M $ 5.9M +20% $10.2M $16.6M +62% Other $ 0.3M $ 0.2M $ 0.9M $0.7M TOTAL $12.8M $16.2M +26% $29.2M $46.7M +60% R E V E N U E M I X Y T D T h r o u g h 9 / 3 0 / 2 1 Numbers may not add
Slide 34: Gross Margin
Gross Margin 34 Q3 2020 Q3 2021 YoY YTD Q1- Q3 2020 YTD Q1- Q3 2021* YoY Gross Margin $ $7.0M $8.9M +27% $15.1M $25.5M +69% Gross Margin % 55% 55% 52% 55% Expected expansion driven by: • Sales growth • Product mix • Overhead absorption efficiencies • Cost reduction projects for OverStitch mid-60%s Y
Slide 35: Capitalization
Capitalization 1. Market Capitalization and Enterprise Value with Pre-Funded Warrants are non-GAAP items; Common shares outstanding at September 30, 2021, were 29,829,697; Pre-funded warrants outstanding at September 30, 2021 were 13,948,875 | 2. Long-Term Debt – Matures March 2025, Senior secured,
Slide 36: Mid-term target revenue growth and investment priorities
leadaccelerate • Advance commercial organization • Drive medical education to increase awareness • Support R&D pipeline • Expand gross margin L E V E R A G E C L I N I C A L S U P P O R T • Broader awareness • Additional indications • Expanded geographies energize I N V E S T TO P E N E T R AT E STA
Slide 37: Appendix
sSapollo were at. Kousnhe
Slide 38: Appendix: Selected Financial Results
Appendix: Selected Financial Results In 000s except percentages 2Q 2021 1Q 2021 FY 2020 4Q 2020 3Q 2020 2Q 2020 1Q 2020 FY 2019 4Q 2019 3Q 2019 2Q 2019 1Q 2019 Revenue $16,610 $13,857 $42,048 $12,860 $12,826 $5,644 $10,718 $50,713 $11,989 $11,259 $14,254 $13,211 Gross Margin 54.9% 54.2% 52.9% 55.9%
Slide 39: Operating Expenses
Operating Expenses In 000s except percentages 2Q 2021 1Q 2021 QoQ 2Q 2021 2Q 2020 YoY 1H 2021 1H 2020 YoY R&D $2,550 $1,928 32% $2,550 $1,815 41% $4,478 $3,962 13% % of Revenue 15.4% 13.9% 15.4% 32.2% 14.7% 24.2% G&A $5,338 $4,069 31% $5,338 $2,157 148% $9,407 $5,496 71% % of Revenue 32.1% 29.4% 32.
Apollo Endosurgery — Investor Presentation (October 2021) on 6ix